Opinion
Video
Author(s):
Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.
Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Revisit the OncLive On Air Episodes From February 2024
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC